Terminated PHASE4 INTERVENTIONAL 3-arm NCT01246011

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

Sponsor: GlaxoSmithKline

Conditions Coronary Artery Bypass Graft Surgery Presence of Heparin/Platelet Factor 4 Antibody

Updated 7 times since 2017 Last updated: Oct 16, 2017 Started: Nov 30, 2010 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Enrollment was too slow.

Other terminated trials from GlaxoSmithKline

See all terminations from GlaxoSmithKline

This PHASE4 trial investigates Coronary Artery Bypass Graft Surgery and Presence of Heparin/Platelet Factor 4 Antibody and is currently terminated or withdrawn. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE4
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE4

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Massachusetts General Hospital

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States